Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    TopAbstracts in Glaucoma 08/25/2008 - (DGNews)
    TopAbstracts in Glaucoma 07/28/2008 - (DGNews)
    Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk - (DGNews)
    TopAbstracts in Glaucoma 06/30/2008 - (DGNews)
    FDA Approves Triamcinolone Acetone Formulation for Ocular Use - (DGNews)

    News archive

     Recent webcasts/CME - Glaucoma
      Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes
      Glaucoma Progression: Detection and Management
      Managing Concomitant Eye Diseases: Expert Views on Glaucoma and Dry Eye
      Topics in Glaucoma Management: Systemic Effects of Medications
      Update on Glaucoma Treatment: ACT: Applying Trial Data on Fixed-Combination Therapy to Daily Clinical Practice

      Webcasts/CME archive

       Recent cases - Glaucoma
        Good Functional Recovery Following Intervention for Delayed Suprachoroidal Haemorrhage Post Bleb Needling: A Case Report
        Acute Bilateral Simultaneous Angle Closure Glaucoma After Topiramate Administration
        Topiramate-Induced Bilateral Angle-Closure Glaucoma
        Bilateral Acute Angle Closure Glaucoma as a Presentation of Isolated Microspherophakia in an Adult: Case Report
        Vascular Compression of the Optic Chiasm Resembling Glaucoma-Like Visual Field Defects

        Cases archive
          




        my personal edition > glaucoma > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Glaucoma Response Seen with Bimatoprost in Latanoprost Non-Responders

        Ophthalmology

        03/28/2003
        By Harvey McConnell


        Most patients with primary open angle glaucoma who did not respond to latanoprost, 0.005% 2D were successfully treated with bimatoprost 0.03% 2D in a small trial by Italian ophthalmologists.

        Of 15 patients who responded to bimatoprost, 12 had a higher incidence of trace-to-mild conjunctival hyperemia than those using latanoprost, report Dr. S. A. Gandolfi and Dr. L. Cimino, University of Parma, Parma.

        Their prospective, randomised, cross-over clinical trial tested the efficacy of bimatoprost for lowering intraocular pressure (IOP) among patients with primary open-angle glaucoma or ocular hypertension who did not respond to latanoprost.

        Patients had two 30-day treatment periods separated by a 30-day washout period. Either treatment was in a single eye only.

        Eligibility criteria were as follows: IOP of more 22 mmHg in both eyes on current treatment following three separate readings more than 24 hours apart; angle wide open in both eyes; no pseudoexfoliation and/or pigment dispersion in either eye; documented medical history consistent with a less than 10% IOP decrease in both eyes following 2 month treatment with daily latanoprost 0.005%.

        Clinicians measured a number of variables. These included IOP (Goldmann applanation tonometry, readings at 8 AM, 12 noon, 4 PM, 8 PM, and 12 midnight); visual acuity measured by Early Treatment of Diabetic Retinopathy Study chart, logarithm of the minimum angle of resolution; estimate of conjunctival hyperemia based on five standard photographs, which were graded as "none," "trace," "mild," "moderate," or "severe".

        At the end of the study the clinicians found mean and standard deviation IOP data were 24.7 mm Hg at baseline, 24.8 mm Hg after washout, 24.1 mm Hg after latanoprost treatment, 18.1 mm Hg after bimatoprost treatment (P<0.0001). IOP on bimatoprost proved lower than both baseline and latanoprost (P=0.0001).

        Thirteen of the 15 patients showed at least a 20% IOP decrease with bimatoprost treatment. None of the 15 patients showed a similar 20% decrease of IOP after 30 days of latanoprost treatment. No significant IOP changes were observed in the untreated eye in any patient.

        Trace-to- mild conjunctival hyperemia was recorded more often during the bimatoprost treatment (P=0.035).
        Ophthalmology 2003 Mar;110:3:609-14.

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send